title: Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
abstract: OBJECTIVE
  Homologous recombination (HR) is frequently impaired in sporadic high-grade serous ovarian carcinoma (sHGSOC) due to deficiencies in BRCA1/2 genes, a situation associated with hypersensitivity to platinum compounds. Alterations in other genes can also cause HR deficiency. Preclinical data show that RAP80 is an HR-pathway-related gene that influences BRCA1 activity. RAP80 has been reported to affect outcome in some solid neoplasms. This study investigates the role of RAP80 in sHGSOC survival.
  
  
  METHODS
  mRNA expression of RAP80 was analyzed in tumor samples from 35 patients who postoperatively received standard platinum-based chemotherapy. The effects of RAP80 expression on progression-free survival (PFS) and overall survival (OS) were examined by means of Cox regressions. The clinical variables known to have prognostic value (FIGO stage, residual disease at surgery, and debulking surgery) were included as covariates in the analysis. BRCA1 was analyzed given the moderate correlations with RAP80.
  
  
  RESULTS
  Median follow-up, PFS and OS were 61.3, 20.2 and 62.8 months, respectively. Low RAP80 expression levels were associated with shorter PFS (HR = 1.449, p = 0.007) and OS (HR = 1.331, p = 0.047).
  
  
  CONCLUSIONS
  This is the first study to show a potential prognostic role of RAP80 expression in patients with HGSOC. The results suggest that HR deficiency due to low RAP80 expression is not associated with hypersensitivity to platinum compounds in sHGSOC.
authors.affiliation:  Medical Oncology Department, Catalan Institute of Oncology, Badalona - Spain.| Department of Medicine, Autonomous University of Barcelona, Barcelona - Spain.
authors.forename: Margarita
authors.initials: M
authors.lastname: Romeo
authors.affiliation:  Translational Research Unit, Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona - Spain.
authors.forename: Niki
authors.initials: N
authors.lastname: Karachaliou
authors.affiliation:  Translational Research Laboratory, Institut d'Investigació Germans Trias i Pujol, Badalona - Spain.
authors.forename: Imane
authors.initials: I
authors.lastname: Chaid
authors.affiliation:  Translational Research Laboratory, Institut d'Investigació Germans Trias i Pujol, Badalona - Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Queralt
authors.affiliation:  Translational Research Laboratory, Institut d'Investigació Germans Trias i Pujol, Badalona - Spain.
authors.forename: Itziar
authors.initials: I
authors.lastname: De Aguirre
authors.affiliation:  Pathology Department, Hospital Germans Trias i Pujol, Badalona - Spain.
authors.forename: María
authors.initials: M
authors.lastname: Del Carmen Gómez
authors.affiliation:  Faculty of Medicine, Universidad Alcala de Henares, Madrid - Spain.
authors.forename: María
authors.initials: M
authors.lastname: Sanchez-Ronco
authors.affiliation:  FIDMAG Germanes Hospitalàries - CIBERSAM, Sant Boi de Llobregat - Spain.
authors.forename: Joaquim
authors.initials: J
authors.lastname: Radua
authors.affiliation:  Translational Research Laboratory, Institut d'Investigació Germans Trias i Pujol, Badalona - Spain.
authors.forename: José Luís
authors.initials: JL
authors.lastname: Ramírez
authors.affiliation:  Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona - Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D002352:Carrier Proteins / Q000235:genetics*; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D004268:DNA-Binding Proteins; D005260:Female; D005500:Follow-Up Studies; D056488:Histone Chaperones; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009687:Nuclear Proteins / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D004268:DNA-Binding Proteins; D056488:Histone Chaperones; D009687:Nuclear Proteins; D012333:RNA, Messenger; C466234:UIMC1 protein, human